Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases

BMC Urology

Volumn 10, Issue , 2010, Pages

  Nieder, Carsten ^a,b   Haukland, Ellinor ^a   Pawinski, Adam ^a   Dalhaug, Astrid ^a  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; RADIOISOTOPE; ZOLEDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATHOLOGIC FRACTURE; PROGNOSIS; PROSTATE CANCER; RISK FACTOR; SPINAL CORD COMPRESSION; SPINE METASTASIS; BONE TUMOR; COMORBIDITY; METASTASIS; MIDDLE AGED; NORWAY; PREVALENCE; PROSTATE TUMOR; RISK ASSESSMENT; SPINAL CORD TUMOR; SPINE FRACTURE;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; COMORBIDITY; HUMANS; MALE; MIDDLE AGED; NORWAY; PREVALENCE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SPINAL FRACTURES; SPINAL NEOPLASMS;

EID: 78650373583     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-10-23     Document Type: Article

References (19)

1. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. E Hernes A Kyrdalen R Kvåle E Hem O Klepp K Acrona SD Fosså BJU Int 2010 105 805 811 10.1111/j.1464-410X.2009.08834.x 19735258
2. Chemotherapy in patients with castration-resistant prostate cancer. HJ Meulenbeld P Hamberg R de Wit, Eur J Cancer 2009 45 Suppl 1 161 171 10.1016/S0959-8049(09)70029-2 19775615
3. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. MR Smith RJ Cook R Coleman J Brown A Lipton P Major Yj Hei F Saad, Urology 2007 70 315 319 10.1016/j.urology.2007.03.071 17826496
4. Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression. N Aass SD Fosså Radiother Oncol 2005 74 259 265 10.1016/j.radonc.2004.12.001 15763306
5. Bone metastases: improving the therapeutic index. HI Scher LW Chung, Semin Oncol 1994 21 630 656 7939753
6. Clinical features of metastatic bone disease and risk of skeletal morbidity. RE Coleman, Clin Cancer Res 2006 12 6243s 6249s 10.1158/1078-0432. CCR-06-0931 17062708
7. Vertebral fracture assessment using a semi-quantitative technique. HK Genant CY Wu C van Kuijk M Nevitt, J Bone Miner Res 1993 8 1137 1148 10.1002/jbmr.5650080915 8237484
8. Assessment of vertebral fractures in osteoporosis research. HK Genant, J Rheumatol 1997 24 1212 1214 9195538
9. Cancer in Norway 2007 - Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway, Oslo: Cancer Registry of Norway 2008
10. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. S Halabi EJ Small PW Kantoff MW Kattan EB Kaplan NA Dawson EG Levine BA Blumenstein NJ Vogelzang, J Clin Oncol 2003 21 1232 1237 10.1200/JCO.2003.06.100 12663709
11. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. T Inoue T Segawa T Kamba K Yoshimura E Nakamura H Nishiyama N Ito T Kamoto T Habuchi O Ogawa, Urology 2009 73 1104 1109 10.1016/j.urology.2008.07.062 19394511
12. The cost of treating skeletal-related events in patients with prostate cancer. MJ Lage BL Barber DJ Harrison S Jun, Am J Manag Care 2008 14 317 322 18471035
13. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. SL Greenspan JB Nelson DL Trump JM Wagner ME Miller S Perera NM Resnick, J Clin Oncol 2008 26 4426 4434 10.1200/JCO.2007.15.1233 18802155
14. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. A Berruti M Tucci A Mosca R Tarabuzzi G Gorzegno C Terrone F Vana G Lamanna M Tampellini F Porpiglia A Angeli RM Scarpa L Dogliotti, Br J Cancer 2005 93 633 638 10.1038/sj.bjc.6602767 16222309
15. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. F Saad YM Chen DM Gleason J Chin, Clin Genitourin Cancer 2007 5 390 396 10.3816/CGC.2007.n.022 17956712
16. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. JC Cheville D Tindall C Boelter R Jenkins CM Lohse VS Pankratz TJ Sebo B Davis ML Blute, Cancer 2002 95 1028 1036 10.1002/cncr.10788 12209687
17. A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. A Bayley M Milosevic R Blend J Logue M Gospodarowicz I Boxen P Warde M McLean C Catton P Catton, Cancer 2001 92 303 310 10.1002/1097-0142(20010715)92:2<303::AID- CNCR1323>3.0.CO;2-F 11466683
18. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. M Tucci A Mosca G Lamanna F Porpiglia M Terzolo F Vana C Cracco L Russo G Gorzegno M Tampellini M Torta G Reimondo M Poggio RM Scarpa A Angeli L Dogliotti A Berutti, Prostate Cancer Prostatic Dis 2009 12 94 99 10.1038/pcan.2008.10 18332901
19. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. M Lein K Miller M Wirth L Weissbach C May K Schmidt U Haus M Schrader K Jung, Prostate 2009 69 624 632 10.1002/pros.20917 19143027